Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BNOX save search
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
Published: 2024-03-21 (Crawled : 10:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 2.75%
H: 3.74%
C: -6.54%
bnc210 trial results
Bionomics to Present at the 2024 BIO CEO & Investor Conference
Published: 2024-02-22 (Crawled : 22:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: -2.61%
H: 1.79%
C: 1.79%
ceo conference
Bionomics Provides a Review of 2023 and of 2024 Plans
Published: 2024-01-22 (Crawled : 11:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: -4.76%
H: 8.0%
C: 4.0%
review
Bionomics to Present at Biotech Showcase™ 2024
Published: 2024-01-05 (Crawled : 11:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 8.45%
H: 6.38%
C: -8.51%
biotech
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting
Published: 2023-12-06 (Crawled : 13:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 3.39%
H: 9.84%
C: 1.64%
meeting
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder
Published: 2023-10-16 (Crawled : 12:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 5.15%
H: 11.52%
C: 8.58%
bnc210 fda meeting program
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
Published: 2023-09-28 (Crawled : 10:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 480.71%
H: 12.06%
C: -41.08%
bnc210 positive topline trial results
Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD
Published: 2023-09-14 (Crawled : 10:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: -18.99%
H: 10.34%
C: -7.59%
positive update collaboration
Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210
Published: 2023-08-23 (Crawled : 10:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 5.83%
H: 17.32%
C: 9.45%
bnc210 expected study
Quarterly Activities and Cashflow Report - July 31, 2023
Published: 2023-07-31 (Crawled : 12:00) - biospace.com/
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: -23.55%
H: 20.54%
C: 12.32%
report
Quarterly Activities and Cashflow Report
Published: 2023-07-31 (Crawled : 10:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: -23.55%
H: 20.54%
C: 12.32%
report
Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)
Published: 2023-07-25 (Crawled : 10:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: -16.12%
H: 9.34%
C: 0.23%
Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth
Published: 2023-07-03 (Crawled : 10:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 0.0%
H: 5.95%
C: 5.95%
ORGO | $2.86 2.51% 2.62% 3
|
Finance
|
| O: 0.9%
H: 1.82%
C: 0.0%
growth
Bionomics to Present at Upcoming June Investor Conferences
Published: 2023-06-15 (Crawled : 12:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 2.04%
H: 0.0%
C: -2.6%
Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Published: 2023-05-30 (Crawled : 10:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 0.0%
H: 1.73%
C: -5.62%
presentation meeting
Quarterly Activities and Cashflow Report
Published: 2023-04-28 (Crawled : 11:00) - biospace.com/
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 0.0%
H: 9.4%
C: -0.44%
report
Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)Topline results expected in Q3 2023
Published: 2023-04-27 (Crawled : 11:00) - biospace.com/
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 0.0%
H: 8.8%
C: 4.63%
bnc210 expected trial results
Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
Published: 2023-04-27 (Crawled : 11:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 0.0%
H: 8.8%
C: 4.63%
bnc210 trial
Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)
Published: 2023-03-09 (Crawled : 01:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: 6.02%
H: 5.88%
C: -30.43%
bnc210 results study social anxiety disorder phase 2
Quarterly Activities and Cashflow Report
Published: 2023-01-30 (Crawled : 00:00) - globenewswire.com
BNOX | $0.98 2.18% -1.17% 18K
|
n/a
|
| O: -2.49%
H: 2.56%
C: 2.3%
report
Gainers vs Losers
| 53% | 47% |
Top 10 Gainers
HUBC | $1.52 17.83% 4.7M
|
n/a
BCS | $9.27 0.33% 140K
|
Finance
RVMD S | $35.86 0.08% 36K
|
Health Technology
BIIB | $190.59 0.04% 50K
|
Health Technology
CMG | $2898.49 -0.33% 290
|
Consumer Services
BELFB | $55.57 -0.82% 2K
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.